Perspective Therapeutics (CATX) Cost of Revenue (2010 - 2023)

Perspective Therapeutics has disclosed Cost of Revenue across 14 years of filings, most recently posting -$4.9 million for Q4 2023.

• Cost of Revenue for Q4 2023 came in at -$4.9 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2023 was -$1.7 million (changed N/A YoY), and the FY2022 annual result was $2.8 million, down 43.15% from the prior year.
• Cost of Revenue came in at -$4.9 million for Q4 2023 at Perspective Therapeutics, down from $1.4 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $3.2 million in Q2 2021 to a low of -$4.9 million in Q4 2023.
• The 5-year median for Cost of Revenue is $702000.0 (2021), against an average of $547473.7.
• Across the five-year window, Cost of Revenue tumbled 179.85% in 2019 and surged 947.04% in 2021, its largest moves.
• Perspective Therapeutics' Cost of Revenue stood at $666000.0 in 2019, then slipped by 7.06% to $619000.0 in 2020, then grew by 13.41% to $702000.0 in 2021, then increased by 13.96% to $800000.0 in 2022, then plunged by 707.88% to -$4.9 million in 2023.
• The last three Cost of Revenue figures came in at -$4.9 million (Q4 2023), $1.4 million (Q3 2023), and $911000.0 (Q2 2023), per Business Quant data.